- Report
- October 2024
- 192 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- October 2024
- 190 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- April 2025
- 164 Pages
Global
From €5225EUR$5,450USD£4,366GBP
- Report
- March 2025
- 175 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- July 2024
- 142 Pages
Global
From €2875EUR$2,999USD£2,402GBP
- Report
- July 2024
- 164 Pages
Global
From €2397EUR$2,500USD£2,003GBP
- Report
- July 2024
- 162 Pages
Africa
From €2397EUR$2,500USD£2,003GBP
- Report
- November 2022
- 353 Pages
Global
From €4893EUR$5,282USD£3,950GBP
- Report
- October 2023
- 75 Pages
Global
From €5704EUR$5,950USD£4,766GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1438EUR$1,500USD£1,202GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- April 2023
- 110 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Report
- June 2019
- 15 Pages
Japan
€9587EUR$10,000USD£8,010GBP
Integrase inhibitors are a class of antiretroviral drugs used to treat HIV/AIDS. They work by blocking the action of the HIV-1 integrase enzyme, which is responsible for the integration of the viral DNA into the host cell's genome. This prevents the virus from replicating and spreading throughout the body. Integrase inhibitors are generally used in combination with other antiretroviral drugs to maximize their effectiveness.
Integrase inhibitors are an important part of the HIV/AIDS treatment landscape, as they are effective at suppressing the virus and reducing the risk of HIV-related complications. They are also well-tolerated, with few side effects.
Some companies in the Integrase Inhibitors market include Gilead Sciences, ViiV Healthcare, Merck, and Janssen Pharmaceuticals. Show Less Read more
